Identification of Friend or Foe: The Laboratory Challenge ...

Identification of Friend or Foe: The LaboratoryChallenge of differentiating M-Proteins fromMonoclonal antibody TherapiesJohn R. Mills1* and David L. Murray1 Background:Since thefirst monoclonal antibody (mAb) therapy hit the market in 1996, the number ofdisorders treated with this class of therapeutics has seen tremendous growth, with over 50 antibody -based therapeutics currently approved for use in the US and Europe. This class of therapeutics recentlymade profound progress in the treatment of refractory multiple myeloma (MM). Treating MM with themAbs will Challenge the Laboratory 's ability to differentiate exogenous mAbs being used to treat pa-tients from endogenous mAbs associated with :An overview of the therapeutic mAbs (t-mAbs) developed for the treatment of MM is pro-vided. The anticipated impact of these therapies on patient care, Laboratory testing, and clinical re-search is discussed. Efforts underway to develop strategies and technologies to help laboratoriesaddress the growing Challenge of mAb interferences are :Laboratories can implement risk mitigation strategies at the preanalytical and postana-lytical phase of testing to reduce the likelihood of reporting false-positive M- protein results inpatients receiving t-mAbs.

Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies John R. Mills 1* and David L. Murray ...

Tags:

  Form, Identification, Laboratory, Challenges, Protein, Friends, Therapies, Antibody, Monoclonal, Friend or foe, Differentiating, The laboratory challenge of differentiating, Proteins from monoclonal antibody therapies

Information

Related search queries